Fig. 3: SCT versus no SCT analyses. | Blood Cancer Journal

Fig. 3: SCT versus no SCT analyses.

From: Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

Fig. 3: SCT versus no SCT analyses.

Multivariate analysis by Cox proportional hazards model with SCT as time-dependent covariate (left) and landmark analysis (right) for overall survival in patients who did or did not receive SCT in A TP53 wild-type patients, B TP53 monoallelic mutated patients, and C TP53 biallelic mutated patients. Overall survival is calculated from the date of MDS diagnosis. BM bone marrow, CG cytogenetics, HR hazard ratio, IPSS-R revised International Prognostic Scoring System, NR not reached, SCT stem cell transplantation, t-MDS therapy-related MDS.

Back to article page